Compare Stocks: QNCX, CBUS, PMN, and ADCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.00 +3.9%	$1.14	$0.78 ▼ $4.98	$127.23M	1.89	1.31 million shs	1.09 million shs
CBUS Cibus	$1.70	$1.70	$1.09 ▼ $4.19	$129.93M	1.61	162,876 shs	102,583 shs
PMN Promis Neurosciences	$14.51 -2.7%	$13.21	$6.27 ▼ $27.40	$130.12M	-0.23	133,019 shs	7,173 shs
QNCX Quince Therapeutics	$33.93 +5.7%	$22.45	$15.10 ▼ $909.98	$34.51M	1.36	35,685 shs	9,536 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-0.76%	-18.65%	-70.62%	-67.88%
CBUS Cibus	0.00%	-3.95%	-4.49%	+23.19%	+30.77%
PMN Promis Neurosciences	0.00%	-2.36%	+15.07%	+32.15%	+10.57%
QNCX Quince Therapeutics	0.00%	-0.32%	+85.61%	+54.23%	-89.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.00 +3.9%	$1.14	$0.78 ▼ $4.98	$127.23M	1.89	1.31 million shs	1.09 million shs
CBUS Cibus	$1.70	$1.70	$1.09 ▼ $4.19	$129.93M	1.61	162,876 shs	102,583 shs
PMN Promis Neurosciences	$14.51 -2.7%	$13.21	$6.27 ▼ $27.40	$130.12M	-0.23	133,019 shs	7,173 shs
QNCX Quince Therapeutics	$33.93 +5.7%	$22.45	$15.10 ▼ $909.98	$34.51M	1.36	35,685 shs	9,536 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-0.76%	-18.65%	-70.62%	-67.88%
CBUS Cibus	0.00%	-3.95%	-4.49%	+23.19%	+30.77%
PMN Promis Neurosciences	0.00%	-2.36%	+15.07%	+32.15%	+10.57%
QNCX Quince Therapeutics	0.00%	-0.32%	+85.61%	+54.23%	-89.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	401.30% Upside
CBUS Cibus	2.00	Hold	$9.00	429.41% Upside
PMN Promis Neurosciences	2.88	Moderate Buy	$34.00	134.32% Upside
QNCX Quince Therapeutics	2.33	Hold	$260.00	666.28% Upside

Current Analyst Ratings Breakdown

Latest QNCX, CBUS, PMN, and ADCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$29.00
8/20/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$68.00
8/18/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$70.00
8/17/2026	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/12/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.57	N/A	N/A	($1.79) per share	-0.56
CBUS Cibus	$3.64M	35.70	N/A	N/A	$0.19 per share	8.95
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$5.51 per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($34.73) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
CBUS Cibus	-$127.08M	-$1.65	N/A	N/A	N/A	-2,258.89%	-287.03%	-27.99%	N/A
PMN Promis Neurosciences	-$39.72M	-$8.54	N/A	N/A	N/A	N/A	-143.09%	-109.15%	11/11/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)

Latest QNCX, CBUS, PMN, and ADCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/13/2026	Q2 2026	CBUS Cibus	-$0.19	-$0.29	-$0.10	-$0.29	$1.70 million	$0.99 million
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.38	-$1.28	+$0.10	-$1.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CBUS Cibus	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
CBUS Cibus	N/A	1.62	1.62
PMN Promis Neurosciences	N/A	7.85	7.85
QNCX Quince Therapeutics	N/A	14.52	2.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CBUS Cibus	33.81%
PMN Promis Neurosciences	50.13%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
CBUS Cibus	29.91%
PMN Promis Neurosciences	1.50%
QNCX Quince Therapeutics	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	127.67 million	121.16 million	Optionable
CBUS Cibus	48	76.43 million	53.57 million	Optionable
PMN Promis Neurosciences	5	8.97 million	8.83 million	Not Optionable
QNCX Quince Therapeutics	60	1.02 million	945,000	Optionable

QNCX, CBUS, PMN, and ADCT Headlines

Recent News About These Companies

Craig Hallum Begins Coverage on Quince Therapeutics (NASDAQ:QNCX)

August 22 at 1:54 AM | americanbankingnews.com

Quince Therapeutics (NASDAQ:QNCX) Cut to "Sell" at Wall Street Zen

August 22 at 1:07 AM | americanbankingnews.com

Cantor Fitzgerald Reaffirms "Overweight" Rating for Quince Therapeutics (NASDAQ:QNCX)

August 20 at 1:43 AM | americanbankingnews.com

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

May 24, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

May 18, 2026 | seekingalpha.com

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026 | globenewswire.com

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60

May 15, 2026 | msn.com

Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80

April 28, 2026 | msn.com

Quince Therapeutics Delays Annual 10-K Filing

April 27, 2026 | theglobeandmail.com

Quince Therapeutics settles $16.4M debt with $5.5M payment

March 30, 2026 | msn.com

Why did QNCX stock surge 40% in pre-market today?

March 30, 2026 | msn.com

Quince Therapeutics Settles Approximately $16.4 Million of Debt

March 30, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, CBUS, PMN, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.00 +0.04 (+3.89%)

As of 08/21/2026 03:58 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Cibus NASDAQ:CBUS

$1.70 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Promis Neurosciences NASDAQ:PMN

$14.51 -0.40 (-2.68%)

As of 08/21/2026 04:00 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Quince Therapeutics NASDAQ:QNCX

$33.93 +1.82 (+5.67%)

As of 08/21/2026 04:00 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, CBUS, PMN, and ADCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, CBUS, PMN, and ADCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, CBUS, PMN, and ADCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, CBUS, PMN, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

Cibus NASDAQ:CBUS

Promis Neurosciences NASDAQ:PMN

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, CBUS, PMN, and ADCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, CBUS, PMN, and ADCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, CBUS, PMN, and ADCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, CBUS, PMN, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

Cibus NASDAQ:CBUS

Promis Neurosciences NASDAQ:PMN

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools